Nanomix Awarded BARDA Contract for Development of Rapid, Mobile, Point-of-Care Assays to Detect COVID-19 Infection
Nanomix, a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that the company has been awarded up to approximately $570,000 in funding from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. These funds support development and testing of COVID-19 point-of-care tests that will run on the Nanomix eLab analyzer, which provides results in less than 15 minutes.
Read More →